“In light of the challenges encountered in the first quarter of 2024, we are intensifying our efforts to drive growth,” said Jim Corbett, CEO of AVITA Medical. “While our account conversion rate impacted our quarterly revenue, we remain optimistic for the full year. With the recent launch of PermeaDerm in March and the upcoming launch of RECELL GO, along with our deeper understanding of the VAC processes and timelines, we believe that we will meet the lower end of our previously provided annual revenue guidance range of $78.5 million to $84.5 million. We remain committed to delivering value and making a positive impact on the lives of our patients.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RCEL:
- AVITA Medical Updates Expected First Quarter 2024 Revenue
- Avita Medical submits response to FDA for Recell Go PMA
- AVITA Medical Submits Response to FDA, Resuming Review Clock for RECELL GO PMA Supplement
- AVITA Medical to Present at TD Cowen 44th Annual Health Care Conference
- AVITA Medical to Host Investor Webinar Briefing
